Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


US grants Pacific Edge patent for melanoma detection


US grants Pacific Edge patent for melanoma detection

4 September 2014

The United States Patent Office has granted Pacific Edge patent protection for 'Prognosis Prediction for Melanoma'. The patent covers the technology being used to develop the melanoma prognostic test that will enable clinicians to distinguish aggressive and life threatening melanomas from those that are not as aggressive.

“It is the aggressive tumours that will kill you” Pacific Edge Chief Executive Officer David Darling says.

The test applies a gene signature to a tissue sample taken from the melanoma to detect its aggressiveness allowing clinicians to prescribe the appropriate level of treatment. Specifically, the test in development identifies aggressiveness in Stage III melanomas.

Pacific Edge partnered with the Ludwig Institute of Cancer Research, the world’s largest not-for-profit cancer research organisation, to develop the technology. This successful partnership has enabled Pacific Edge to develop the prototype product for detecting aggressiveness in Stage III melanomas.

The USA is the third jurisdiction after China and New Zealand to grant patent protection for the ‘Prognosis Prediction for Melanoma’ test that is in the development stage.

The melanoma test is one of several cancer products that the Company has worked up to prototype level prior to focussing resources on the successful launch and further development of its Cxbladder technology for detecting and managing bladder cancer. Cxbladderdetect is now being commercialised in the United States, New Zealand, Australia, and soon in Spain. The second product in the program, Cxbladdertriage, is scheduled for commercial release in New Zealand later this year.

Pacific Edge was founded to use the latest developments in molecular biology to provide actionable diagnosis that can contribute to a clinically meaningful difference in cancer detection and the management of that cancer. It is the driving force of our research and product development program” David Darling says.

“Cxbladder is a prime example. It is a quick, cost effective, non-invasive and highly accurate cancer detection test that enables clinicians to detect urothelial carcinomas, including cancers of the bladder, from a small urine sample.”

Pacific Edge’s ongoing development program includes clinical and ‘User Programs’ to validate Cxbladdertriage, a new product positioned to enable physians and clinicians to segregate out patients who have presented to the clinician with blood in their urine, who do not have bladder cancer thereby saving considerable clinical work-up cost. Another of the Company’s products in late-stage development and validation is Cxbladderpredict, a product that will enable clinicians to determine the severity of bladder cancer disease and enable them to non-invasively segregate superficial tumours from invasive tumours.

The Company’s portfolio of intellectual property continues to grow and includes patents for a gastric cancer test as well as melanoma and bladder cancers.

“We are now leveraging the experience gained in launching Cxbladder to the world’s largest health care market, the USA, into other products for the USA. We are also now looking to other targeted international markets” David Darling says.

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Statistics: Business Research And Development Up 29 Percent

Computer services and machinery manufacturing firms led the way in an almost 30 percent lift in business spending on research and development (R&D) in 2016, Stats NZ said today. Businesses spent $1.6 billion on R&D in 2016, up $356 million (29 percent) from 2014. More>>

ALSO:

China Shopping: NZ-China FTA Upgrade Agreed Among Slew Of New Deals

New Zealand Prime Minister Bill English and China Premier Li Keqiang signed off a series of cooperation deals spanning trade, customs, travel and climate change and confirmed commencement of official talks on an upgrade to the nine-year old free-trade agreement between the two countries. More>>

ALSO:

Media: TVNZ Flags Job Cuts To Arrest Profit Decline

Chief executive Kevin Kenrick said the changes were aimed at creating "a sustainable future video content business for TVNZ in an ever-changing media market." More>>

ALSO:

Reserve Bank: Wheeler Keeps OCR At 1.75%

Reserve Bank governor Graeme Wheeler kept the official cash rate unchanged at 1.75 percent, as expected, and reiterated his view that the benchmark rate doesn't need shifting for the foreseeable future. More>>

ALSO:

Trade Plans: Prime Minister's Speech To International Business Forum

"The work to improve public services, build infrastructure, and solve social problems is possible only because we have enjoyed sustained, solid economic growth. A big reason for that is the Government’s consistent agenda of economic reform, and our determination to open up more opportunities for trade with the world." More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news